The content is available as a PDF (398.2 KB).
letter . 2020 Aug 14:ciaa1209. doi: 10.1093/cid/ciaa1209
Baricitinib as treatment for COVID-19: friend or foe of the pancreas?
Christopher Cerda-Contreras
1, Laura Nuzzolo-Shihadeh
2, Adrián Camacho-Ortiz
2, Eduardo Perez-Alba
2,✉
Christopher Cerda-Contreras, MD
1
Servicio de Medicina Interna, Hospital Universitario Dr. José Eleuterio
González, Universidad Autónoma de Nuevo León, Monterrey Mexico
Find articles by Christopher Cerda-Contreras
Laura Nuzzolo-Shihadeh, MD
2
Servicio de Infectología, Hospital Universitario Dr. José Eleuterio
González, Universidad Autónoma de Nuevo León, Monterrey Mexico
Find articles by Laura Nuzzolo-Shihadeh
Adrián Camacho-Ortiz, MD, PhD
2
Servicio de Infectología, Hospital Universitario Dr. José Eleuterio
González, Universidad Autónoma de Nuevo León, Monterrey Mexico
Find articles by Adrián Camacho-Ortiz
Eduardo Perez-Alba, MD
2
Servicio de Infectología, Hospital Universitario Dr. José Eleuterio
González, Universidad Autónoma de Nuevo León, Monterrey Mexico
Find articles by Eduardo Perez-Alba
1
Servicio de Medicina Interna, Hospital Universitario Dr. José Eleuterio
González, Universidad Autónoma de Nuevo León, Monterrey Mexico
2
Servicio de Infectología, Hospital Universitario Dr. José Eleuterio
González, Universidad Autónoma de Nuevo León, Monterrey Mexico
✉
Corresponding author: Eduardo Perez-Alba MD, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León. Madero y Gonzalitos s/n, Colonia Mitras Centro, Monterrey, Nuevo León, Mexico. C.P. 64460, E-mail: md.eduardo.perez@gmail.com, Phone: +52 811 799 8705
Received 2020 Jul 14.
© The Author(s) 2020. Published by Oxford University Press for the
Infectious Diseases Society of America. All rights reserved. For permissions, e-mail:
journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC7454364 PMID: 32797239
See letter "Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019
(COVID-19) Coagulopathy? Jorgensen et al" in volume 73 on page e3980.
See letter "Baricitinib: Impact on COVID-19 coagulopathy?", ciaa1208.